ATYR Q3 2024 Earnings — aTyr Pharma, Inc. Revenue & Financial Results | Market Cap Arena

ATYRaTyr Pharma, Inc.

$93M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$18M

Net Income

-$17M

EPS (Diluted)

$-0.23

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$752,000

Balance Sheet

Total Assets

$92M

Total Liabilities

$26M

Stockholders' Equity

$65M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$353,000	-100.0%
Gross Profit	$0	-$640,000	+100.0%
Operating Income	-$18M	-$13M	-43.8%
Net Income	-$17M	-$11M	-52.2%